Abstract
METHODS:
Sixty-eight patients with advanced HCC were assigned to a control group of 36 and a treatment group of 32. The control group was treated with best supportive treatment (BST) and the treatment group was given XAP plus BST. XAP was administered daily by iv and the treatment course was lasted for 30 days for both groups. The immediate therapeutic efficacy, Karnofsky performance status (KPS) scores, and the changes in immunity indicators (CD3 + , CD4 + and CD8 + T cells) were measured and compared before and after treatment. The progression-free survival (PFS) rate and overall survival (OS) rate in the 2 groups were analyzed.
RESULTS:
The immediate therapeutic efficacy and KPS of the treatment group were better than those in the control group (P<0.05). Patients in the treatment group had higher percentages of CD3 and CD4 T-lymphocytes in peripheral blood than those in the control group (P<0.05). The median survival time was 27.0 weeks in the treatment group and 24.5 weeks in the control group. The 6-months cumulative survival rates in the treatment and control groups were 33.3% and 25.0% , respectively, with no significant difference (P>0.05). The PFS was 18 weeks in the treatment group and 15 weeks in control group (P<0.05).
INRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common tumours. It is difficult to diagnose HCC at its early stage due to its fast progress. When definitely diagnosed, HCC usually has already developed to its advanced stage. Moreover, the fatality rate of HCC is very high, making it the third cause of cancer death. 1 Conventional treatment for HCC include surgical removal, liver transplant, ablation, chemoembolization and molecular targeted therapy. 2 However, none of these methods is ideal due to various reasons. For example, it is estimated the treatment with surgical removal or radiofrequency ablation can only be offered to 10% of HCC patients with smaller size of tumors.
high recurrence rate of the disease, poor efficacy of radioactive therapy and chemoembolization, and high likelihood of intrahepatic spread and distant metastasis. Due to these limitations of currently available surgical and oncological treatments and difficulties in early diagnosis, there is an urgent need to find new efficient therapies to treat advanced HCC. The current study is aimed at identifying treatment options to prolong the life span and to improve the quality of life (QOL) of patients with advanced HCC. Xiaoaiping is a traditional Chinese herbal medicine extracted from the roots of Marsdenia tenacissima mainly found in Yunnan and Guizhou provinces of China. According to the theories of Traditional Chinese Medicine, Marsdenia tenacissima, bitter and slightly sweet in taste and cool in nature, an effective anticancer drug acting on lung, stomach, and bladder channels, can prevent certain poisons and relieve cough and asthma. 4 Marsdenia tenacissima contains steroidal saponins, alkaloids, flavonoids, polysaccharides, resins, pigments and other chemical constituents, some of which have excellent antitumor activities. 5 However, there are few reports on basic and clinical researches addressing the anticancer effects of Marsdenia tenacissima. Especially, systematic research addressing its effect on the survival rate of cancer patients is scarce. In this study, we saw a promising effect of Xiaoaiping injection (XAP) on advanced HCC in 32 patients by measuring their progression-free survival (PFS) rate and Karnofsky performance status (KPS) score.
MATERIALS AND METHODS

Patients
All patients signed a consent form according to the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Fujian University of Traditional Chinese Medicine. Patients diagnosed with advanced HCC at our hospital from September 2009 to March 2011 (China Classification System ⅢA/ Ⅲ B) were included in this study. Patients who underwent surgery and received or were receiving interventional therapy were excluded. Diagnosis of HCC was based on the level of serum alpha-fetoprotein (AFP≥ 400 ng/mL), imaging of ultrasound (iU22, Philips Healthcare, Bothell, WA, USA) and computed tomography (Asteion multiple, Toshiba, Kawasaki, Japan), or liver biopsy with AFP <400 ng/mL. 6 Patients with a KPS score ≥60 and an estimated life expectancy of >3 months were recruited in the study. Sixty-eight subjects of advanced HCC were randomly assigned to the treatment group and control group for a single-blind clinical study. Among the 32 cases in the treatment group were 23 males and 9 females aged 32 to 75 years, 49 years on average, 10 cases of portal vein thrombosis and 30 cases of hepatitis B virus (HBV) infection, 13 
Treatment
In the treatment group, while the patients were receiving BST including nutritional support, improving liver function and relieving pain, intravenous drip was administered with 40 mL of XAP (Sanhome Pharmaceutical Co. Ltd., Nanjing, China) added to 250 mL of 5% glucose or normal saline, QD, for 30 consecutive days as one therapeutic course. Another 30-day treatment course was conducted after a 2-week interval. In the control group, only BST was administered for 30 days.
Evaluation
Evaluation of immediate efficacy: before and after one month of treatment, immediate efficacy was evaluated according to response evaluation criteria in solid tumors (RECIST) 7 with ultrasonography or computed tomography. The efficacy is classified into 4 grades: complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD). The total effective rate was calculated with the formula: [(Number of cases with CR + PR + SD)/Total number of cases] x 100%. 
Assessment of general immune function
QOL of patients
KPS scoring is used to quantify the QOL of cancer and other patients in terms of their general well-being and activities of daily life. 8 The pre-treatment and post-treatment KPS scores of both groups were evaluated.
Survival rate
The primary and secondary end points for this study were PFS and OS. PFS was defined as the interval from the onset of treatment to disease progression or death. OS was defined as the time from the date of diagnosis to date of death or the date of the last follow-up visit. All patients were followed until death or November 1, 2011.
Adverse reactions
Adverse reactions due to XAP infusion, such as shivering, fever or allergy, were monitored and categorized into different degrees of severity, 0-IV, according to the World Health Organization (WHO) evaluation criteria 1998. 9 
Statistical analysis
Differences of enumeration data were evaluated with Chi-square test and differences of measurement data with t-test at a 95% confidence level. Survival analysis was conducted with Kaplan-Meier and Long-rank tests. The survival rate was calculated in terms of weeks. All analyses were performed with SPSS 13.0 software (SPSS Inc, Chicago, IL, USA).
RESULTS
Immediate effect
The total effective rate was 71.8% in the treatment group and 47.2% in the control group with significant difference between the two groups (P=0.039) ( Table 1) . + subpopulations of T cells in the peripheral blood of the two groups showed no significant differences before treatment. After treatment, the percentages in the treatment group were much higher than those in the control group (P<0.05) ( Table 2) .
Changes in immunity indicators
Comparison of KPS scores
The pre-treatment KPS score was 63±6 in the control group and 62±6 in the treatment group (P>0.05). After treatment, the KPS score was 53± 9 in the control group and 67±8 in the treatment group (P<0.05) (Figure 1) .
OS rate
The median survival rate was (24.5 ± 1.4) weeks [95% confidence interval (CI), 21.7-27.2 weeks] and 6-month cumulative survival rate is 25.0% in the control group. The median survival rate was (27.0 ± 2.4) weeks [95% CI, 22.3-31.7 weeks] and 6-month cumulative survival rate was 33.3% in the treatment group. The survival curves (Figure 2 ) of the two groups were not significantly different from one another by Log-rank test.
Progression-free survival
The median PFS was (15.0 ± 1.1) weeks [95% CI, 12.9-17.1 weeks] in the control group and (18.0±2.0) weeks [95% CI, 14.1-21.9 weeks] in the treatment group. The PFS curve (Figure 3) , of the treatment group was significantly different from that in the control group by Log-rank test (P<0.05).
No toxic or side effects were found in the treatment.
DISCUSSION
Modern pharmacological studies have demonstrated that XAP can not only prevent cultured cancer cells from proliferation, such as Bel-7404, HepG2 and SGC-7901 cells, and induce their differentiation, but also improve the chemotherapy efficacy of 5-fluorouracil (5-FU). [10] [11] [12] [13] In addition, XAP has minimal toxicity to immune and hematopoietic stem cells. On the other hand, XAP can improve the proliferation of T and B lymphocytes. 14 Moreover, XAP improved the sensitivity of non-small-cell lung cancer (NSCLC) cells carrying T790M or K-ras mutations to gefitinib. 15 The promising anti-tumour effect of XAP in vitro encourage further study to explore its potential as an anti-cancer medication. The chemical composition of Marsdenia tenacissima extract is complex. Studies have focused on the C21 steroidal glycosides, the main active substances. 5, 16 In addition, in chemical and pharmacological studies of XAP, the relationship between its pharmacodynamic properties and clinical action is not very clear, and systematic, multi-center clinical study on XAP are rare. In the majority of clinical studies, the main outcomes measured were short-term effects, QOL and immune function, 17, 18 but the survival rate of the patients was seldom addressed. This study showed that the SD rate (as an indicator of immediate efficacy) in the treatment group was significantly higher than that in the control group, indicating that XAP might inhibit tumour growth in clinical setting. There was a significant difference between the KPS scores in the two groups, indicating that XAP 19 These changes reduce the immune surveillance function, which in turn impairs the ability of the immune system to inhibit the development of tumours. In this study, the CD3 + and CD4 + T lymphocytes and the CD4 + /CD8 + ratio in the treatment group increased significantly after treatment, compared to the corresponding values in the control group. There was also an increase in the CD8 + lymphocytes. These data demonstrated that XAP effectively alleviated the deficits in immune function caused by the proliferation of tumour cells in advanced HCC patients. In our study, there was no difference in OS between both groups, but PFS was 15 weeks in the control group and 18 weeks in the treatment group (P<0.05). 3 weeks longer than that in the control group suggested XAP's clinical significance for the patients with advanced HCC. In summary, the results of this study indicated that XAP improved QOL, immune function, effectively inhibited further development of the cancer and delayed disease progression, which suggests that XAP may be an effective medication for patients with advanced HCC. 
